기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
The Role of Gamma Knife Radiosurgery for Diffuse Astrocytomas
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • The Role of Gamma Knife Radiosurgery for Diffuse Astrocytomas
  • The Role of Gamma Knife Radiosurgery for Diffuse Astrocytomas
저자명
Kim. Kyung-Hyun,Park. Yong-Sook,Chang. Jong-Hee,Chang. Jin-Woo,Park. Yong-Gou
간행물명
Journal of Korean neurosurgical society
권/호정보
2006년|39권 2호|pp.102-108 (7 pages)
발행정보
대한신경외과학회
파일정보
정기간행물|ENG|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Objective : The management of diffuse astrocytomas is one of the most controversial areas in clinical neurooncology. There are numerous reviews and editorials outlining the difficulties in the management of these lesions. In this study, we assess the role of Gamma Knife radiosurgery[GKS] for diffuse astrocytomas. Methods : Twenty-three patients with a diffuse astrocytoma were treated with GKS as a primary or adjuvant method from February 1995 to October 2003. The mean marginal dose was $13.6;[8.5{sim}17.5]Gy$ and the mean maximal dose was $27.3;[17.0{sim}35.0]Gy$. Local control and the pattern of radiologic response were evaluated. The probable factors affecting local control, such as tumor volume, margin dose, previous history of craniotomy or stereotactic biopsy, and the presence or absence of previous radiotherapy were statistically analyzed. The average duration of follow-up was 39.7 [$11.3{sim}101.5$] months after GKS. Results : Of the 23 lesions treated, 16 lesions [69.6%] were controlled during the follow-up period. The mean progression-free interval was 57.4 months and the 5-year progression-free rate was 68%. Only tumor volume was found to be a statistically significant factor for local control. Smaller tumors were better controlled by GKS; it was significantly effective in tumors with less than $10cm^3$ volume. Conclusion : GKS could be a valuable therapeutic modality both as a primary treatment and as a postoperative adjuvant therapy in some selected cases.